Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Early Stage Parkinson's Disease Clear all
Terminated Phase 2 Interventional Results available

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

NCT02906020
View directory record Official record
Conditions
Parkinson's Disease
Interventions
venglustat GZ/SAR402671, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone in Early Parkinson's Disease

NCT01280123
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pioglitazone, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Flexible-Dose Trial in Early Parkinson's Disease (PD)

NCT04223193
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Fresno, California • Boca Raton, Florida • Maitland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 4, 2026, 9:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

NCT03100149
View directory record Official record
Conditions
Parkinson's Disease
Interventions
RO7046015, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 4, 2026, 9:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331
View directory record Official record
Conditions
Parkinsons Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroplasticity in Parkinson's Disease

NCT05286736
View directory record Official record
Conditions
Parkinson, Parkinson Disease
Interventions
Neuroimaging, Quantitative assessments
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

NCT06976268
View directory record Official record
Conditions
Parkinson Disease
Interventions
BHV-8000 10mg, BHV-8000 20 mg, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

NCT05348785
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122, BIIB122-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

NCT00332917
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2009 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Not applicable Interventional

Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease

NCT05308238
View directory record Official record
Conditions
Parkinson Disease
Interventions
Occupational therapy intervention group, Disease management education group
Behavioral
Lead sponsor
San Jose State University
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Jose, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 4, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

NCT02847650
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, PF-06649751
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
20
States / cities
Phoenix, Arizona • Boca Raton, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Phase 2a Study of VTX3232 in Parkinson's Disease

NCT06556173
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
VTX3232
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

NCT02055274
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LY03003, Neupro
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Long Beach, California • Orlando, Florida • Douglasville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

NCT02807675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Isradipine in Early Parkinson Disease

NCT02168842
View directory record Official record
Conditions
Parkinson Disease
Interventions
Isradipine, Placebo (for Isradipine)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

SLV308 for Treatment of Patients With Early Parkinson's Disease

NCT00269516
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2008 · Synced Oct 4, 2026, 9:24 PM EDT
Not listed Phase 1 Interventional

Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson's Disease (Engage-PD)

NCT04922190
View directory record Official record
Conditions
Parkinson Disease
Interventions
Physical Activity Coaching
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

NCT00335166
View directory record Official record
Conditions
Early Stage Parkinson Disease
Interventions
Pardaprunox, pramipexole, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 4, 2026, 9:24 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830
View directory record Official record
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

NCT00594165
View directory record Official record
Conditions
Early-Stage Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508
View directory record Official record
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

NCT04928287
View directory record Official record
Conditions
Parkinson Disease
Interventions
HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 4 Interventional Results available

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
31 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 4, 2026, 9:24 PM EDT